PropThink-Investment News and Analysis of Biotechnology and Healthcare

Must Read

Duchenne Muscular Dystrophy KOL Investor Call

Obesity & PD-1: History Doesn’t Repeat But It Rhymes

The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...

Read Now

Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...

Insights

With Actavis Support, Trevena Moves Forward with Heart Failure Study

Insights - Trevena, Inc. (TRVN) announced on Monday plans to upsize the phase IIb BLAST-AHF trial, testing TRV027 in acute heart failure (AHF), and to focus on the middle dose being tested in the study. The trial will be expanded from 500 to 620 patients and will weight enrolled patients towards what Trevena characterizes as the most promising dose, 5mg/hr, plus standard heart failure therapy versus placebo plus standard of care.

Read now

Recap

The Top Stories in Healthcare: Our Weekly Recap

Recap - In a major twist for avid investors in the healthcare sector, it was AbbVie (ABBV) that emerged as the winner in a three-way bidding war for Pharmacyclics (PCYC) this week.

Read now

Insights

FDA Official Spoils the Party for Orexigen

Insights - Orexigen Therapeutics (OREX) surged early this week with the release of positive interim study results for Contrave, the company’s approved weight loss drug. Public comments from an FDA official on Thursday evening, however, put a damper on the celebration.

Read now

Research

Conatus’ CMO Resigns Weeks in Front of Data Point for Lead Drug

Research - Conatus Pharmaceuticals' (CNAT) CMO, Dr. Gary Burgess, tendered his resignation on Thursday. Here's why investors should take note.

Insights

Intra-Cellular Therapies Exemplifies “Raise When You Can” in Biotech

Insights - Intra-Cellular Therapies, Inc. (ITCI) announced a public offering of 4.25 million shares of its common stock on Wednesday morning, prescient in light of the stock’s … Continue Reading

Read now

Insights

Latest Data Bode Well for Orexigen’s Weight Loss Drug, Contrave

Insights - Orexigen Therapeutics (OREX) ripped higher on Tuesday with news that a new – and profoundly important – patent has been issued for Contrave, Orexigen’s approved weight … Continue Reading

Read now

Research

Baxter’s Recent Gene Therapy Data: An Underappreciated Derisking Event for uniQure

Research - UniQure went through some interesting de-risking two weeks back with the release of initial data (the first publicly) from Baxter International’s (BAX) Hemophilia B gene therapy program, … Continue Reading

Read now

Proprietary Thinking for the Intelligent Investor

Must Read

Duchenne Muscular Dystrophy KOL Investor Call

Obesity & PD-1: History Doesn’t Repeat But It Rhymes

Latest Posts

With Actavis Support, Trevena Moves Forward with Heart Failure Study

The Top Stories in Healthcare: Our Weekly Recap

FDA Official Spoils the Party for Orexigen

Conatus’ CMO Resigns Weeks in Front of Data Point for Lead Drug

Intra-Cellular Therapies Exemplifies “Raise When You Can” in Biotech

Latest Data Bode Well for Orexigen’s Weight Loss Drug, Contrave

Baxter’s Recent Gene Therapy Data: An Underappreciated Derisking Event for uniQure

Which Best Describes You?

Professional Edge

Proven Returns

Proprietary Access

Professional Edge

Proven Returns

Proprietary Access

Must Read

Duchenne Muscular Dystrophy KOL Investor Call

Obesity & PD-1: History Doesn’t Repeat But It Rhymes

Modular Medical Submits 510(k) for Insulin Patch Pump

Latest Posts